Highlights Current treatment recommendations for patients with type 2 diabetes mellitus (T2DM) advise the use of glucagon-like peptide 1 receptor agonists, with a majority of them administered subcutaneously or needing stringent fasting conditions before or after consumption. A phase 2b randomized clinical trial was carried out in 411 adults with T2DM to investigate the efficacy, safety, and tolerability of danuglipron, which doesn’t require any specific conditions of administration. Glucagon-like peptide 1 receptor (GLP-1R) agonists are recommended for type 2 diabetes mellitus (T2DM) patients based on their glycemic status and the presence of comorbidities.
1 In a phase 1 clinical trial, a small-molecule GLP-1R agonist called danuglipron has been shown to reduce body weight and glycemic indexes in T2DM patients who were on metformin therapy. 2 We have summarized the phase 2b…
